RPL17 and hepatocellular carcinoma: The combination of PD - 1 blockade with arsenic sulfide treatment can further enhance the cytotoxic capabilities of CD8+ T cells, resulting in a significantly synergistic therapeutic effect against HCC (Figure 7).